Search clinical trials for: ABT-555

Total 1520 results

AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection (VOYAGE-1)

Hepatitis C Virus (HCV)

China, Korea, Republic of, Singapore
Pfizer

Completed

12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation

Smoking Cessation

Japan
Abt Associates
Hennepin County Human Services and Public Health Department

Completed

Evaluation of the Teen Outreach Program in Hennepin County, Minnesota

Sexual Behavior | Pregnancy Early

United States
Pfizer

Completed

12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation

Smoking Cessation

United States
AbbVie (prior sponsor, Abbott)

Completed

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Alzheimer's Disease

United States, Canada, France, Germany, Greece, South Africa, United Kingdom
AbbVie

Completed

Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Alzheimer's Disease

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

ABT-751 in Treating Young Patients With Refractory Solid Tumors

Sarcoma | Kidney Cancer | Unspecified Childhood Solid Tumor, Protocol Specific | Ovarian Cancer | Brain and Central Nervous System Tumors | Neuroblastoma | Liver Cancer | Extragonadal Germ Cell Tumor | Childhood Germ Cell Tumor

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer

Neoplasms | Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

ABT-510 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)
Abbott Medical Devices

Completed

Real-World Outcomes Study on Subjects Treated With Radiofrequency Ablation (ROSTRA)

Pain

Spain, United States, Belgium, France, Germany, Netherlands
Abbott Medical Devices

Active, not recruiting

Expanded Clinical Study of the Tendyne Mitral Valve System

Mitral Valve Regurgitation

United States, Norway, Germany, France, United Kingdom, Netherlands, Switzerland, Australia, Italy, Sweden
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV) (Navigator)

Hepatitis C Virus
AbbVie

No longer available

Expanded Access to Navitoclax

Myelofibrosis | Lymphoblastic Lymphoma | Acute Lymphocytic Leukemia (ALL)

United States
Okuvision GmbH
CONET GmbH - Clinical Operations Network

Completed

Retrospective NIS to Evaluate the Patient Benefit of TES

Retinitis Pigmentosa

Germany, Switzerland
AbbVie

Withdrawn

A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review

Acute Myeloid Leukemia
Pfizer

Completed

Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking

Smoking Cessation

Colombia, Mexico, Egypt, Jordan, Brazil, Costa Rica, Lebanon, Saudi Arabia, South Africa, United Arab Emirates, Venezuela
Abbott

Completed

A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.

Breast Cancer

United States
AbbVie

Not yet recruiting

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia
AbbVie (prior sponsor, Abbott)

Completed

A Study of ABT-806 in Subjects With Advanced Solid Tumor Types

Advanced Solid Tumors

United States
AbbVie

Withdrawn

An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men

Hypogonadism | Testosterone Deficiency

United States
Drexel University

Recruiting

An Acceptance-Based Healthy Lifestyle Intervention for Diverse Adolescents

Overweight and Obesity

United States
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before (MALACHITE 1)

Chronic Hepatitis C Infection
Abbott
Statistika Consultoria Ltda

Completed

Efficacy and Safety of the Use of Venocur Triplex® in Patients With Chronic Venous Insufficiency

Venous Insufficiency

Brazil
AbbVie (prior sponsor, Abbott)

Completed

ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors

Advanced Solid Tumors

United States
Pfizer

Completed

Varenicline Observational Investigation In The Cessation of Smoking (CHOICES)

Smoking Cessation

Belgium, Hungary, Greece, Slovenia
AbbVie

Completed

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection (GEODE II)

Hepatitis C Virus (HCV)
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil

Chronic Hepatitis C Infection
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma

Brain and Central Nervous System Tumors

United States
AbbVie

Completed

Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease

Chronic Hepatitis C | Hepatitis C Virus | Severe Renal Impairment | Compensated Cirrhosis | End-stage Renal Disease
University of Arkansas

Withdrawn

Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer

Carcinoma, Non-Small-Cell-Lung

United States
Abbott

Completed

Comparison of Fenofibric Acid Bioavailability From ABT-335 Capsules

Healthy

United States
Abbott

Completed

A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia

Schizophrenia

United States
Roswell Park Cancer Institute
AbbVie

Completed

Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | Metastatic Prostate Carcinoma in the Soft Tissue | Castration Levels of Testosterone | Prostate Carcinoma...

United States
AbbVie

Recruiting

A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan

Chronic Lymphocytic Leukemia

Japan
AbbVie
Genentech, Inc.

Completed

A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States, Australia, Germany, United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Pfizer

Completed

An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation

Smoking Cessation

United States, United Kingdom, Belgium, France, Netherlands
Pfizer

Completed

A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation

Smoking Cessation

United States, Canada, Norway, Sweden, United Kingdom, Czech Republic, Denmark
Pfizer

Completed

A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline

Smoking Cessation

United States, Australia
University of Roma La Sapienza

Not yet recruiting

A Prospective muLticEnter Registry in chrONic coronARy synDrOme (LEONARDO)

Coronary Artery Disease
Takeda

Active, not recruiting

A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During Pregnancy

Constipation | Pregnancy

United States
Pfizer

Completed

A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation

Smoking Cessation

United States
AbbVie

Recruiting

A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada (LIVEN)

Acute Myeloid Leukemia

Canada
Abbott

Terminated

A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Lung Cancer

United States, Canada, Ireland, United Kingdom
Radiant Research

Completed

ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study

Dyslipidemia

United States
Abbott
Genentech, Inc.

Completed

Assess the Oral Bioavailability of New ABT-263 Formulations

Chronic Lymphocytic Leukemia | Lymphomas | Leukemias

United States
University of Colorado, Denver

Active, not recruiting

Evaluation of Malglycemia Via Continuous Glucose Monitoring in the Pediatric HSCT Population

Hematopoietic Stem Cell Transplantation

United States
AbbVie

Active, not recruiting

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

Myelofibrosis (MF)

United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, New Zealand, Poland, Puerto Rico, Russian Federation, Serbia, South... and more
Abbott

Completed

A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease

Alzheimer's Disease

United States

3

Subscribe